Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Aptose Announces Closing of Public Offering of Common Shares

Dec 19, 2019 4:02pm EST

Aptose Announces Pricing of Public Offering of Common Shares

Dec 17, 2019 8:00am EST

Aptose Announces Proposed Public Offering of Common Shares

Dec 16, 2019 4:19pm EST

Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting

Dec 09, 2019 11:00am EST

Aptose Presents Highlights From Corporate Event At ASH

Dec 07, 2019 11:00am EST

Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer

Dec 04, 2019 7:30am EST

Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference

Dec 02, 2019 7:30am EST

Aptose to Present at BIO-Europe Conference

Nov 07, 2019 7:30am EST

Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting

Nov 06, 2019 9:54am EST

Aptose Reports Results for the Third Quarter Ended September 30, 2019

Nov 05, 2019 4:02pm EST
RSS
  • Prev
    • 1...
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • 20
    • ...32
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences